Rapivab (peramivir) is the first neuraminidase
inhibitor available in an intravenous formulation.
The neuraminidase inhibitors are the only
recommended antivirals for influenza treatment.
Amantadine and rimantadine antivirals are not
active against influenza B. In addition, high
levels of resistance exist among influenza A
H3N2 and H1N1 strains. The other
neuraminidase inhibitors include oral Tamiflu
(oseltamivir) and inhaled Relenza (zanamivir).
This document reviews the known safety and
efficacy of peramivir and discusses its place in
therapy.